Sumitomo Pharma Presents Urology and Oncology Data at AUA 2024 Annual Meeting
MARLBOROUGH, Mass., May 7, 2024 /PRNewswire/ -- Sumitomo Pharma America, Inc., (SMPA) today announced the presentation of data from URO-901-3005, a Phase 3 randomized, double-blind, parallel-group, fixed-dose study evaluating the efficacy, safety, and tolerability of vibegron (GEMTESA®) versus placebo over 24 weeks in men living with overactive bladder (OAB) and receiving pharmacological therapy for benign prostatic hyperplasia (BPH) at the American Urological Association (AUA) Annual Meeting. Following the podium presentation at AUA, these results were published in Journal of Urology.
- Following the podium presentation at AUA, these results were published in Journal of Urology .
- "There is currently no approved treatment for persistent OAB symptoms in men who are receiving treatment for BPH.
- We are happy to share these results with the scientific community at AUA."
- "We are proud to have our urology and oncology teams together and among the leaders at AUA sharing positive data that underpins our steadfast commitment to those living with unmet urological conditions."